Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 17/20 | 0.36 |
| ▸ | DRD2 | P14416 | 16/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.35 |
| ▸ | MLNR | O43193 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22892323 | 0.90 | DRD3 (0.41) | HTR2CDRD3DRD2JAK2JAK3 | |
| SCHEMBL16221371 | 0.77 | HTR2C (0.43) | HTR2CDRD3DRD2 | |
| SCHEMBL10313038 | 0.76 | HTR2C (0.48) | HTR2C | |
| SCHEMBL21326114 | 0.75 | HTR2C (0.42) | HTR2CDRD3DRD2 | |
| Hydrochloric Acid SCHEMBL30474224 | 0.75 | CHRM4 (0.47) | HTR2C | |
| SCHEMBL3389292 | 0.72 | HRH3 (0.58) | — | |
| SCHEMBL30474385 | 0.71 | PNMT (0.42) | HTR2C | |
| SCHEMBL17585077 | 0.71 | HRH3 (0.53) | DRD3DRD2 | |
| SCHEMBL17624122 | 0.71 | DRD3 (0.38) | DRD3DRD2 | |
| SCHEMBL30474149 | 0.71 | HTR2C (0.48) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3495363-B1 | NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 RECEPTOR ANTAGONISTIC EFFECT | SHIONOGI & CO (JP) | 2023-08-23 | — | — | EP | disclosed |
| US-11345716-B2 | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect | SHIONOGI & CO., LTD. (JP) | 2022-05-31 | — | — | US | disclosed |
| US-20210009607-A1 | NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 ANTAGONISTIC EFFECT | SHIONOGI & CO., LTD. (JP) | 2021-01-14 | — | — | US | disclosed |
| US-10870660-B2 | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect | SHIONOGI & CO., LTD. (JP) | 2020-12-22 | — | — | US | disclosed |
| US-20190161501-A1 | NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 ANTAGONISTIC EFFECT | SHIONOGI & CO., LTD. (JP) | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345716-B2 | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect | DRD3, DRD4, DRD2 | HTR2C 104/4885DRD3 1/4885DRD2 3/4885 |
| US-10870660-B2 | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect | DRD3, DRD4, DRD2 | HTR2C 104/4885DRD3 1/4885DRD2 3/4885 |
| US-20210009607-A1 | NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 ANTAGONISTIC EFFECT | DRD3, DRD4, DRD2 | HTR2C 104/4885DRD3 1/4885DRD2 3/4885 |
| US-20190161501-A1 | NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 ANTAGONISTIC EFFECT | DRD3, DRD4, DRD2 | HTR2C 104/4885DRD3 1/4885DRD2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.